П

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number:	3235-0287									
Estimated average burden										
hours per response:	0.5									

See

footnote⁽²⁾ See

footnote⁽²⁾

T

I

D

Check this box if no longer subject to	
Section 16. Form 4 or Form 5	
obligations may continue. See	
Instruction 1(b).	

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Schuth Alexander O.				2. Issuer Name and Ticker or Trading Symbol <u>Denali Therapeutics Inc.</u> [DNLI]							Relationship of Reporting Person(s) to Issuer Check all applicable) Director 10% Owner				
(Last) C/O DENALI T	(First)	(Middle)			ate of Earliest Tran 17/2023	saction (Month	n/Day/Year)	×	below)	Officer (give title Other (specify below) below) COFO and Secretary				
161 OYSTER POINT BLVD.				4. If Amendment, Date of Original Filed (Month/Day/Year)						Line)	. Individual or Joint/Group Filing (Check Applicable ine)				
(Street) SOUTH SAN FRANCISCO CA 94080										X	Form filed by Or Form filed by Mo Person	1 0			
(City)	(State)	(Zip)		Rule 10b5-1(c) Transaction Indication											
					Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.										
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned															
Date			2. Transactio Date (Month/Day/Y	Execution Date,		3. Transaction Code (Instr. 8)		4. Securities Disposed Of			5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
					Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(
Common Stock 07/17/20			07/17/202	23		М		10,000	A	\$5.28	538,691(1)	I	See footnote ⁽²⁾		

nmon Stock \$29.6⁽⁴⁾ 07/17/2023 <mark>s</mark>(3) 10,000 Common Stock D 528,691 07/18/2023 s⁽³⁾ \$30.01(5) 518,989 Common Stock 9,702 D Common Stock 131,822(6)(7) Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

L															
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transac Code (Ir 8)				6. Date Exerc Expiration Da (Month/Day/Y	ate	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (right to buy)	\$5.28	07/17/2023		М			10,000	(8)	03/07/2027	Common Stock	10,000	\$0	68,937	D	

Explanation of Responses:

1. Exercised shares were issued to the Schuth Family Trust.

2. The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee.

3. The sales reported by the Reporting Person were affected pursuant to a Rule 10b5-1 trading plan adopted September 30, 2022.

4. The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from \$29.33 to \$29.94 per share. Upon request by the Commission staff, the Issuer, or a securityholder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

5. The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from \$30.00 to \$30.04 per share. Upon request by the Commission staff, the Issuer, or a securityholder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

6. Includes 1,030 shares acquired under the ESPP Purchase on May 31, 2023.

7. Includes 119,156 RSUs.

8. 25% of the shares subject to the option vested on March 8, 2018 and an additional 1/48 of the shares vested monthly thereafter.

Remarks:

/s/ Alexander Schuth

07/19/2023 Date

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.